Intercept Pharmaceuticals (ICPT) Earning Somewhat Favorable News Coverage, Analysis Finds

Media headlines about Intercept Pharmaceuticals (NASDAQ:ICPT) have been trending somewhat positive recently, Accern reports. The research group identifies positive and negative news coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Intercept Pharmaceuticals earned a media sentiment score of 0.09 on Accern’s scale. Accern also assigned media headlines about the biopharmaceutical company an impact score of 46.1066813298034 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.

Here are some of the media headlines that may have effected Accern Sentiment Analysis’s analysis:

A number of equities analysts recently commented on ICPT shares. Wedbush restated a “buy” rating and issued a $253.00 price objective on shares of Intercept Pharmaceuticals in a report on Monday, November 20th. Leerink Swann restated a “hold” rating and issued a $60.00 price objective on shares of Intercept Pharmaceuticals in a report on Tuesday, November 28th. ValuEngine upgraded Intercept Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Friday, December 1st. BidaskClub downgraded Intercept Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Thursday, December 7th. Finally, Deutsche Bank started coverage on Intercept Pharmaceuticals in a report on Tuesday, December 12th. They issued a “buy” rating and a $106.00 price objective on the stock. Four equities research analysts have rated the stock with a sell rating, ten have issued a hold rating and ten have issued a buy rating to the stock. The company currently has an average rating of “Hold” and an average price target of $128.75.

Intercept Pharmaceuticals (NASDAQ ICPT) opened at $63.36 on Tuesday. Intercept Pharmaceuticals has a twelve month low of $51.05 and a twelve month high of $135.59. The company has a current ratio of 4.31, a quick ratio of 4.31 and a debt-to-equity ratio of 21.71. The company has a market capitalization of $1,635.47, a P/E ratio of -4.40 and a beta of -1.92.

Intercept Pharmaceuticals (NASDAQ:ICPT) last announced its quarterly earnings results on Wednesday, February 14th. The biopharmaceutical company reported ($4.43) EPS for the quarter, missing the consensus estimate of ($3.39) by ($1.04). Intercept Pharmaceuticals had a negative net margin of 275.18% and a negative return on equity of 267.95%. The company had revenue of $37.69 million for the quarter, compared to analyst estimates of $39.01 million. During the same quarter last year, the business earned ($4.84) EPS. The company’s revenue for the quarter was up 173.1% on a year-over-year basis. equities research analysts forecast that Intercept Pharmaceuticals will post -12.6 EPS for the current year.

TRADEMARK VIOLATION WARNING: “Intercept Pharmaceuticals (ICPT) Earning Somewhat Favorable News Coverage, Analysis Finds” was published by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are accessing this article on another website, it was stolen and republished in violation of US and international trademark & copyright legislation. The correct version of this article can be read at

About Intercept Pharmaceuticals

Intercept Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. The Company’s product candidates have the potential to treat orphan and more prevalent diseases for which there are limited therapeutic solutions.

Insider Buying and Selling by Quarter for Intercept Pharmaceuticals (NASDAQ:ICPT)

Receive News & Ratings for Intercept Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intercept Pharmaceuticals and related companies with's FREE daily email newsletter.

Leave a Reply